Study of Metformin Pharmacogenetics in Twins

University of Southern Denmark34 enrolled

Overview

The trough concentration of metformin will be examined in monozygotic and dizygotic twins. Current twin study will determine the total weight of genetics on the trough concentration of metformin.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Type 2 Diabetes

Interventions

MetforminDRUG

6 days treatment with metformin to steady-state

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-40 years * Both twins has to be included * Dizygotic twin pairs has to be same sex * Informed consent given * Healthy condition Exclusion Criteria: * Chronical/daily alcohol abuse * Hypersensitivity to metformin * Ingestion of drugs containing topiramate or x-ray contrast fluids * For women: Positive pregnancy test/breastfeeding at the beginning of the trial. No use of safe anticonceptives

Locations (1)

Clinical Pharmacology

Odense C, Denmark

Outcomes

Primary Outcomes

Heritability

The trough concentrations of metformin in twin pairs will be used to determine the effect of heritability on metformin trough concentrations. This will give insight to the weight that genetic factors have on metformin pharmacokinetics at steady-state.

Time frame: After 6 days of metformin treatment

Secondary Outcomes

Single nucleotide polymorphisms (SNPs)

The effect of SNPs on trough metformin concentration

Time frame: After 6 days treatment with metformin

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.